IDiyas

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Richard Waltz Harper

USPTO Granted Patents = 30

Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 242(Granted Patents)


Location History:

  • Whitehall, MI (US) (2004)
  • Indianapolis, IN (US) (1977 - 2005)
  • Fort Worth, TX (US) (2007)
  • New Braunfels, TX (US) (2018 - 2019)

Company Filing History:

goldMedal26 out of 4,442 
 
Eli Lilly and Company
 patents
silverMedal3 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1977-2019

Loading Chart...
30 patents (USPTO):
1. 10176696 - Apparatus and process for measuring gaseous emissions from an engine (2019-01-08),
2. 10054204 - Variable output planetary gear set with electromagnetic braking (2018-08-21),
3. D556982 - Shoe sole (2007-12-11),
4. 6939890 - sPLA2 inhibitors (2005-09-06),
5. 6933313 - Substituted carbazoles as inhibitors of sPLA2 (2005-08-23),
6. 6831095 - Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors (2004-12-14),
7. 6780099 - Roof ventilation system (2004-08-24),
8. 6713645 - Substituted tricyclics (2004-03-30),
9. 6541499 - Antithrombotic agents (2003-04-01),
10. 6448422 - Chromogenic compound (2002-09-10),
11. 6391908 - Oxime amide indole type sPLA2 inhibitors (2002-05-21),
12. 6391901 - Thrombin inhibitors (2002-05-21),
13. 6359136 - Antithrombotic agents (2002-03-19),
14. 6353128 - Phenyl acetamides as sPLA2 inhibitors (2002-03-05),
15. 6350774 - Antithrombotic agents (2002-02-26),

Title: Richard Waltz Harper: Innovator in sPLA2 Inhibitors

Introduction: Richard Waltz Harper, based in Indianapolis, Indiana, is a prolific inventor with an impressive record of 26 patents. His work primarily focuses on developing innovative compounds aimed at addressing inflammatory diseases, showcasing his commitment to advancing medical science.

Latest Patents: Among Harper's notable patents are his latest innovations related to sPLA2 inhibitors. One such patent discloses a class of novel indole compounds that can inhibit the sPLA-mediated release of fatty acids, providing potential treatment options for conditions like septic shock. Another patent emphasizes substituted carbazoles with a specific formula (I) that also serve as inhibitors of sPLA2, detailing their utility in treating inflammatory conditions by targeting the same biochemical pathways.

Career Highlights: Richard Harper is a key contributor at Eli Lilly and Company, a leading pharmaceutical company known for its extensive research and development efforts in innovative healthcare solutions. His work is instrumental in fostering new therapeutic avenues and enhancing patient care through scientific breakthroughs.

Collaborations: In his innovative journey, Harper collaborates with esteemed colleagues such as Ho-Shen Lin and Daniel Jon Sall. Their collective expertise strengthens the research efforts at Eli Lilly, driving forward the discovery of impactful pharmaceutical interventions.

Conclusion: Richard Waltz Harper stands as a notable figure in the realm of pharmaceutical innovation, with a focus on developing sPLA2 inhibitors that hold promise for treating severe inflammatory diseases. Through his contributions at Eli Lilly and his collaborations with talented coworkers, Harper continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…